A widely-used device that employs brainwaves to help doctors prevent patients from waking up during surgery is no more effective than an older, far less costly technique, according to a rece... Read more
We are constantly being asked about what is going on in our firm’s Mass Torts Section. Lawyers in the Section are currently investigating a number of drugs and medical devices, and are... Read more
Harvard researchers have found a disturbing pattern with drugs that have been pulled off the market. They found that medicines approved right on deadline by the Food and Drug Administration... Read more
It’s come to light that a 2006 study claiming 80% of lung cancer deaths may be prevented with CT scans was actually funded by a tobacco company. The New England Journal of Medicine mad... Read more
It’s now almost certain that Trasylol, an anti-bleeding drug, will stay off the market. A rigorous study found that patients receiving the medication during heart surgery were much mor... Read more
One of my favorite actors, Dennis Quaid, made a noteworthy appearance before a Congressional Committee last month. With his newborn twins steadily recovering from a grave medical error that... Read more
The threat of federal preemption has become a major issue in this country. A most interesting article appeared in the New England Journal of Medicine recently that addressed this issue. The... Read more
The Food and Drug Administration says that a drug proposed by GlaxoSmithKline PLC to treat a bleeding condition decreases bleeding events similar to a placebo. In documents posted to the FDA... Read more
New Jersey Superior Court Judge Carroll Higbee, who oversees all the Vioxx litigation in New Jersey, recently granted a new trial in a Vioxx case won by Merck in 2005. The judge reasoned tha... Read more
Merck & Co. has been playing fast and loose with the truth for years relating to its testing and marketing of Vioxx. Finally, in an admission that undermines its core defense in Vioxx-r... Read more
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.